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Sexual contacts are the main spreading route of HIV. This puts sex workers at higher risk of
infection even in populations where HIV prevalence is moderate or low. Alongside condom use,
Pre-Exposure Prophylaxis (PrEP) is an effective tool for sex workers to reduce their risk of HIV
acquisition. However, PrEP provides no direct protection against sexually transmitted infections
(STIs) other than HIV, unlike condoms. We use an empirical network of sexual contacts among
female sex workers (FSWs) and clients to simulate the spread of HIV and gonorrhea. We then
investigate the effect of PrEP adoption and adherence, on both HIV and gonorrhea prevalence. We
also study the effect of a potential increase in condomless acts due to lowered risk perception with
respect of the no-PrEP scenario (risk compensation). We find that when HIV is the only disease
circulating, PrEP is effective in reducing HIV prevalence, even with high risk compensation. Instead,
the complex interplay between the two diseases shows that different levels of risk compensation
require different intervention strategies. Finally, we find that providing PrEP only to the most active
FSWs is less effective than uniform PrEP adoption. Our work shows that the effects emerging from
the complex interactions between these diseases and the available prophylactic measures need to be
accounted for, to devise effective intervention strategies.
INTRODUCTION
Sex workers are disproportionately vulnerable to HIV,
especially in low and middle-income countries [1, 2]. Vi-
olence, stigma, and punitive laws hinder their access to
healthcare services [3]. In addition, scarcely available
condoms, and low bargaining power with clients who
refuse to use them, dramatically increase sex workers’
risk of HIV acquisition [4–6].
Pre-Exposure Prophylaxis (PrEP) represents an addi-
tional prevention tool, and consists in taking regularly
a specific antiretroviral medication. It has the potential
of protecting HIV-uninfected sex workers from acquir-
ing HIV, especially if they cannot use condoms regularly.
Furthermore, access to PrEP helps sex workers have per-
sonal control over their health, with positive implications
∗ E-mail: eugenio.valdano@gmail.com
beyond HIV prophylaxis [7]. High efficacy in reducing
the risk of HIV acquisition in highly adherent individu-
als has been extensively investigated and reported [8, 9].
Notwithstanding, reaching the required adherence among
sex workers might prove difficult, if the roll-out of PrEP
is not supported by formative activities [7, 10–15]. In
addition, PrEP might influence the frequency at which
sex workers use condoms, although no definite evidence
in this sense exists. The potential cause of this is risk
compensation, i.e. an increase in risky behavior sparked
by a decrease in perceived risk [16–18]. If PrEP was
to lead sex workers towards riskier sexual behavior, it
would increase their probability of acquiring other Sex-
ually Transmitted Infections (STIs), such as gonorrhea,
chlamydia, syphilis [19]. This in turn can increase the
risk of acquiring HIV [20], especially if the adherence to
PrEP is not optimal. Consequently, concerns about risk
compensation remain a consistent barrier to PrEP pro-
vision among health care providers [21, 22].
One of the most concerning HIV co-infections is gonor-
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2rhea (NG), caused by the bacteria Neisseria gonorrhoeae.
It occurs in approximately 9.5% of people living with HIV
(PLHIV) [20], and it has been showing increasing antimi-
crobial resistance [23]. The impact of PrEP on gonorrhea
is difficult to assess. On the one hand, lower condom use
could enhance the probability of contracting gonorrhea.
On the other hand, the periodical screenings that are as-
sociated with regular PrEP use may entail a better detec-
tion of gonorrhea (especially in its asymptomatic form),
and lead to a decrease in its prevalence [24]. Summing
up, this is a complex and still open issue.
Mathematical models can help shed light on the com-
plex interaction among HIV, gonorrhea, and prophylaxis,
and inform optimal strategies for PrEP roll-out. Previ-
ous modeling works have focused on predicting the re-
duction in new HIV acquisitions, on the cost-effectiveness
of PrEP in different countries, focusing on different key
populations [25, 26]. However, little attention has been
payed to the interaction between HIV and other STIs
[27]. In addition, they have assumed that sex workers
and clients mix homogeneously, at odds with known re-
sults highlighting the role of complex contact patterns in
shaping epidemic processes [28–32]. Specifically, hetero-
geneities in the number of contacts, and in their occur-
rence in time, are known to impact the performance of
immunization strategies [33] and of interaction between
different [34] pathogens [34–38].
In this study, we simulate the concurrent spread of
HIV and gonorrhea over a network of real sexual contacts
among female sex workers (FSWs) and their male clients,
collected in Brazil over the course of six years [39, 40]. We
investigate the impact of PrEP as a prophylactic measure
additional to condoms, and the role of risk compensation.
We do that both by assuming the spread of HIV only, and
both HIV and gonorrhea. Finally, we study the impact of
nonuniform PrEP adoption on both HIV and gonorrhea
prevalence.
MATERIALS AND METHODS
Dataset
The anonymized dataset is obtained from a Brazilian web
community of posts about self-reported sexual encoun-
ters between female sex workers and male clients. Each
encounter is represented as a link of a bipartite network
composed of N [F ] = 5965 female and N [M ] = 8818 male
nodes. We should notice that 33875 out of the 44088 re-
ported contacts involve a unique pair of nodes. By taking
advantage of this longitudinal nature of the dataset, we
consider daily snapshots of the interactions, resulting in
a temporal network [41] that spans over 1233 days (we
remove the first 1000 days of the original dataset). Re-
peated interactions among the same pair of nodes within
the same day are not considered.
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FIG. 1. The model. Individuals can belong to one of the six
compartments. Susceptible individuals (S) can acquire either
HIV (H, ↓) or gonorrhea (G, →) after a heterosexual contact
with an infected person. Once infected by gonorrhea, individ-
uals become gonorrhea-exposed (GE), i.e. infected by gonor-
rhea but not able to infect others yet. After a certain latency
period, individuals can become gonorrhea-infectious (G) and
thus able to transmit the disease. Once infected by HIV, in-
dividuals are immediately HIV-infectious (H), i.e. able to
infect other susceptible persons. At the same time, HIV-
infectious can also become gonorrhea-exposed (HGE). Again,
after a certain latency period individuals HIV-infectious can
turn gonorrhea-infectious (HG). While recovery from gon-
orrhea is possible, HIV-infected individuals cannot become
susceptible.
Epidemic model
We define a stochastic epidemic model to simulate the
spread of HIV and gonorrhea over the networked popu-
lation. In particular, we use a compartmental model (see
Fig. 1) in which individuals are divided into six different
compartments, according to their status with respect to
the considered diseases:
• S: susceptible individuals who can acquire both
HIV and gonorrhea by means of a sexual contact;
• GE : exposed individuals who have acquired gonor-
rhea but are not yet able to transmit it;
• G: gonorrhea-infectious individuals who have gon-
orrhea and can transmit it;
• H: HIV-infectious individuals who have HIV and
can transmit it;
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Infection probability βM→FG 0.7 [42]
Infection probability βF→MG 0.3 [42]
Latency period 1/MG 3.5 days [42]
Latency period 1/FG 10 days [42]
Infectious period 1/γG 16 months [42]
H
IV
Infection probability βF→MH 0.0057 [43]
Infection probability βM→FH 0.029 [43]
Increase in HIV transm. θ 10 [44]
Efficacy of condoms ηcond 0.8 [45]
Efficacy of PrEP ηPrEP 0.7 [45]
Prob. condom adoption pFcond 0.3 [39]
TABLE I. Summary of the parameters of the model.
H and G stands for HIV and gonorrhea respectively, while M
and F denote the gender dependency of the parameters.
• HGE : HIV-infectious individuals who have also
been exposed to gonorrhea, but can only transmit
HIV;
• HG: infectious individuals who can transmit both
HIV and gonorrhea.
HIV dynamics is thus modeled as a Susceptible-Infected
model for simplicity as it has been done in other anal-
ogous studies [25, 46, 47], while gonorrhea dynamics is
represented as a
Susceptible - Exposed - Infected - Susceptible model.
Transitions among the compartments are controlled by
the transition probabilities listed in Table I. At each time
step (day), a susceptible S individual having a sexual en-
counter can get infected by one or both gonorrhea and
HIV if the partner is infectious. In particular, a suscep-
tible S individual can acquire gonorrhea and become GE
or get infected by HIV and become H with probability
βG and βH , respectively. Notice that there is also a joint
probability of getting both diseases in the same time step
and thus change state from S toHGE (see Fig. 1). Unlike
HIV, individuals that acquire gonorrhea become first ex-
posed and then infectious. The exposed ones (GE) have
a probability G of getting infectious which is inversely
proportional to the average latency period [42]. Individ-
uals transit then from GE to the infectious state G with
a probability G. We include in our model the fact that
gonorrhea increases susceptibility to HIV [44], by mul-
tiplying the transition probability from GE to HG and
from G to HG by a factor θ.
Finally, people with gonorrhea (G and HG) can re-
cover, becoming S or H again with probability γG. As
before, this probability is inversely proportional to the
respective average infectious period.
In order to overcome the limited time span of the
dataset, we impose periodic boundary conditions. HIV
spreads very slowly with respect to the daily time scale
of the network, due to its low transmission probabilities.
This assures that its spread will not critically depend
on our specific choice of dataset extrapolation, as previ-
ous evidence shows [48]. To account for both FSWs and
clients leaving and entering the system, we add vital dy-
namics. More specifically, we assume that at each time
step each individual has a certain probability of being
replaced with a new one of the same type (FSWs with
FSWs, and clients with clients). Moreover, each new in-
dividual enters the system with a probability of being
infected equal to the initial prevalence of the diseases,
to account for the fact that our network is not a closed
system. To fix the replacement probabilities, we wish to
account for the fact that more active individuals might
stay longer in the system. To this end, we divide in-
dividuals into three different activity classes, which are
defined according to the number of sexual encounters:
one encounter (6111 individuals), between one and six
(6443), and more than six encounters (2229). For the
second and third class, we calculate the activity time of
each individual, i.e., the time between her/his first and
last contact, focusing only on the individuals who had
their first interaction in the first 200 time steps. We as-
sume that the replacement probability in each class is
proportional to the inverse of its activity time, and we
fix the proportionality constant so that we reach a steady
endemic state for both diseases. This gives replacement
probabilities of 4 · 10−4 and 1 · 10−4 for the second and
third class, respectively. For the first class, for which we
have no activity time, we fix 5 ·10−4, i.e., we assume that
the individuals with the lowest activity gets replaced the
most often.
In each time step t, the total number of nodes N is
given by the sum of female (F) and male (M) individuals
in all the compartments, which reads
N =
∑
α=F,M
S[α](t) +G
[α]
E (t) +G
[α](t)
+H [α](t) +HG
[α]
E (t) +HG
[α](t).
(1)
Here, we define some macroscopic order parameters that
we will use in the different scenarios. Specifically, we
denote the density of HIV and gonorrhea infectious indi-
viduals of gender α as
h[α](t) =
H [α](t)
N [α]
(2)
and
g[α](t) =
G[α](t)
N [α]
. (3)
We denote with h[α] and g[α] their respective stationary
state. Similarly, the global density of infectious individ-
uals is given by
ρ[α](t) = h[α](t) + g[α](t) + hg[α](t) (4)
4with
hg[α](t) =
HG[α](t)
N [α]
, (5)
being the density of individuals who are both gonorrhea-
infectious and HIV-infectious. Again, we call ρ[α] the
stationary density of infectious for Eq. 4.
Condom use, and risk compensation
We assume the probability of condom use to be pcond =
0.3 per sexual act. It corresponds to the average of what
is measured in [39]. We interpret pcond as the ability of
the FSW to enforce condom use during intercourse with
her client. The lower its value, the lower her bargain-
ing power. We model the impact of risk compensation
on condom use as a rescaling factor to pcond. Therefore,
in the absence of risk compensation (0%), pcond remains
unchanged when PrEP is used. On the other hand for
100% we have full risk compensation and pcond goes to
zero which means that FSWs on PrEP do not use con-
doms.
Modeling Setup
In the analyses, we consider three scenarios, and the
baseline. In the baseline scenario condoms are the only
way of preventing HIV acquisition. In all the other sce-
narios, we add PrEP with different sets of parameters. In
the first scenario, we set high adoption (50% of women)
and high PrEP efficacy (70% reduction in HIV suscep-
tibility). In the second, we set low adoption (10% of
women) keeping high PrEP efficacy (70% reduction in
HIV susceptibility). In the third and last scenario, we
set low adoption (10% of women) and low PrEP efficacy
(40% reduction in HIV susceptibility). The different lev-
els of PrEP efficacy are set to explore different scenarios
of adherence [49]. We run these three scenarios for four
different values of risk compensation: 0% (no risk com-
pensation), 33%, 66%, 100% (full risk compensation).
We start by exploring the spread of HIV without gon-
orrhea in the first two scenarios. Each simulation starts
with an initial prevalence of HIV equal to 10%, in both
FSWs and clients. We run each scenario 20 times, each
over the course of 1.5 · 105 days, to get sufficient statis-
tics. We then introduce gonorrhea and perform the sim-
ulations with the same number of runs and over the same
time span. In this case, as initial condition of each simu-
lation, we set the prevalence of both HIV and gonorrhea
equal to 10%, in both FSWs and clients. We remark that
initial disease prevalence are not the endemic prevalence
of our system. They are only the initial conditions, and
represent the baseline prevalence of the individuals en-
tering the system. The final endemic prevalence are the
result of the infection dynamics on the network.
HIV
FIG. 2. HIV prevalence as a function of the risk com-
pensation in the absence of gonorrhea for FSWs. The
black and green line indicate the scenarios of high (50%, sce-
nario 1) and low adoption (10%, scenario 2) of sex workers
use PrEP, with PrEP efficacy fixed to 70%. The solid line
indicates the median value of the different realizations, while
the area represents the standard deviation.
RESULTS
Uniform PrEP adoption
In this section, we assign uniform probability of PrEP
adoption among FSWs. For the first and second scenar-
ios, without gonorrhea in the system, and for each value
of risk compensation, we normalize the prevalence of HIV
with the baseline in both FSWs and clients(see Fig. 2).
As expected, we find that PrEP use decreases HIV preva-
lence in FSWs with respect to the baseline case. Notably,
risk compensation has very little impact on HIV preva-
lence in both scenarios, as shown in Fig. 2.
Next, we study the simultaneous spread of the two
diseases. Figure 3 shows the impact on HIV and gon-
orrhea prevalence in FSWs, as well as the prevalence of
co-infections. We analyze the second (low PrEP adoption
with high PrEP efficacy) and third (high PrEP adoption
with low PrEP efficacy) scenarios. With low adoption
and high efficacy (blue lines), PrEP is able to constantly
reduce HIV prevalence among FSWs, even in the case of
full risk compensation. The amount of such reduction is
comparable to the case where gonorrhea is absent, and it
is not affected by risk compensation, as seen by compar-
ing Fig. 2 and Fig. 3. This effect, driven by low adoption,
is true in the cases of both high efficacy and low efficacy
(not shown). Low PrEP efficacy simply decreases the
overall impact of PrEP. In addition, the scenario of low
PrEP adoption has little effect on gonorrhea prevalence
with respect to the baseline case. However, we observe a
slight decrease in co-infections (HIV + gonorrhea) when
risk compensation is absent, or low.
We now turn to the scenario of high PrEP adoption
with low PrEP efficacy (orange lines in Fig. 3). In this
case, both HIV prevalence and gonorrhea prevalence are
5FIG. 3. HIV and NG prevalence as a function of the risk compensation. Relative prevalence of HIV (a), NG (b) and
the combined incidence (c). The case of high and low adoption of PrEP corresponds to the ones of Fig. 2. Furthermore, we
introduced two scenarios: one with high efficacy and one with low efficacy that lead to, respectively, 70% and 40% of reduction
in the transmission probability. The solid lines indicate the median values of the different realizations, while the area represents
the standard deviation. The dashed horizontal line denotes the baseline.
sensitive to risk compensation. As expected, low risk
compensation entails a drop in HIV prevalence, and has
no negative effect on gonorrhea prevalence. On the other
hand, it decreases co-infections, as in the other scenario
(low PrEP adoption with high PrEP efficacy). Increas-
ing risk compensation sharply increases both HIV and
gonorrhea prevalence, up to the case of full risk compen-
sation, when HIV prevalence is actually slightly higher
than the baseline. However, this simply represents the
slightly lower efficacy of PrEP with respect to condom,
hence it is sensitive to the specific value of PrEP efficacy
set. The effect of high risk compensation has instead a
marked impact on gonorrhea, with the extreme case of
full risk compensation showing a 15% increase with re-
spect to the baseline.
Targeted PrEP adoption
We now assume PrEP take-up happens preferentially
among highly active FSWs, i.e., those with high num-
bers of sexual acts. Specifically, we divide FSWs in three
classes: the 40% least active, the 40% mid active, and
the 20% most active. We then assume that women in
the first class never adopt PrEP, women in the second
with probability 0.81, and women in the third one (the
most active) always adopt it. These probabilities guar-
antee that the average adoption probability is 50%, to
compare it with the uniform high PrEP adoption sce-
narios, i.e. scenarios 1 and 3. In addition to the low
PrEP efficacy (40%, scenario 3), and high PrEP efficacy
(70%, scenario 1), we explore also perfect PrEP efficacy
(100%). The results are shown in Fig. 4. The first col-
umn reports the impact on HIV prevalence. Clearly, we
observe that increasing PrEP efficacy reduces HIV preva-
lence, for both uniform and targeted adoptions. Unex-
pectedly, for both efficacy 40% (a) and 70% (d) uniform
PrEP adoption consistently outperforms targeted adop-
tion, for every value of risk compensation. In particular,
targeted intervention has a detrimental effect for high
risk compensation, pushing HIV prevalence significantly
above the baseline in the case of 40% PrEP adoption.
When PrEP efficacy is perfect, the drop in HIV preva-
lence is marked (see Fig. 4c)). However, the performance
of the two PrEP adoption strategies changes completely
(see Fig. 4g). Here we observe that targeted adoption
performs much better than uniform adoption. At the
same time, risk compensation plays almost no role, as
women on PrEP are protected no matter their condom
use.
The effect of immunization strategies on gonorrhea
prevalence is shown in Fig. 4b,e,h. Gonorrhea prevalence
is consistently higher than baseline for nonzero risk com-
pensation. We note that the targeted intervention always
increases gonorrhea prevalence more than uniform, albeit
the difference between the two interventions decreases
from lower to higher PrEP efficacy, becoming almost zero
in case of perfect efficacy. This is due to the fact that
targeted adoption is more sensitive to risk compensation
than uniform adoption.
Finally, Fig. 4c,f,i show the impact on co-infections.
The overall behavior is driven by HIV prevalence
(Fig. 4a,b,c). However, for low risk compensation co-
infections are consistently lower than baseline.
Instead of targeting the most active FSWs, another
strategy would be to target the ones with the highest
number of sexual partners. However, we find that the
two quantities are extremely correlated, as Fig. 5 shows,
and we do not exchange any different behavior.
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FIG. 4. HIV and NG prevalence as a function of risk compensation as 50% of the sex workers are using PrEP.
Between the top (a-c), center (d-f) and bottom (g-i) panels the PrEP efficacy varies between 40%, 70% and 100%. The left
(a,d,g), center (b,e,h) and right (c,f,i) columns show the HIV, NG and combined prevalence. The green and red lines indicate
the prevalence as PrEP is distributed uniformly or in a targeted way, respectively. The solid line is the median prevalence over
the different realizations, whereas the area indicates the variance. The dashed horizontal line denotes the baseline.
DISCUSSION
We first considered circulation of HIV only, and ex-
amined the impact of PrEP adoption in a population of
FSWs. We compared the prevalence of HIV with respect
to the baseline scenario of condom use and no PrEP.
We investigated the impact of risk compensation among
FSWs, in terms of a potential reduction in condom use
following PrEP adoption. In this scenario, we found that
risk compensation has a limited effect and does not seem
to compromise the high efficacy of PrEP in reducing HIV
prevalence.
We then studied co-circulation of HIV and gonorrhea,
observing a complex interplay among the two diseases
on one hand, and the two prophylactic tools on the
other (condom, PrEP). Notably, we found two opposite
regimes. In case of low risk compensation (women tend
not to change their behavior towards condoms when they
are on PrEP), our model suggests that providing PrEP
to more women is efficient in reducing HIV prevalence.
Instead, in case of high risk compensation, HIV reduc-
tion requires interventions focusing on increasing PrEP
efficacy in users. This can be attained with supportive
structures and formative activities [7, 11, 12], aimed at
increasing PrEP knowledge, and fighting logistical barri-
ers and stigma [7, 13]. Our results however show that the
existence of risk compensation increases gonorrhea preva-
lence, often even at low levels. This implies that PrEP
diffusion strategies should entail consistent screenings to
minimize the impact of this effect [24].
Finally, we analysed the impact of non-uniform PrEP
7FIG. 5. Number of interactions of sex workers as a
function of their number of clients. The solid red line
indicates a linear fit of the data. The two are highly corre-
lated, which is illustrated by the Spearman rank coefficient of
rs = 0.98± 0.0025.
adoption strategies. We compared the random distribu-
tion of PrEP with a targeted distribution to the most
active FSWs. Surprisingly, and in contrast to previous
findings [33], uniform distribution of PrEP proves more
effective than the targeted distribution. This difference
with previous studies can be explained by the fact that
they only focused on perfect immunization (in our case
translating into 100% effective prophylaxis). Actually,
in the case of imperfect immunization, there is the pos-
sibility of saturation effects. In other words, very ac-
tive FSWs have such a high probability of eventually ac-
quiring HIV, that an imperfect protection cannot provide
substantial protection. Accordingly, it proves more ben-
eficial to target FSWs which are less active, but whose
infection probability is substantially decreased by PrEP.
Obviously, this argument does not apply if immuniza-
tion is perfect, as our findings show. Previous studies on
immunization essentially searched for local rules, which
serve as a proxy to identify highly connected nodes in the
network [33, 50]. However, as our results indicate, such
protocols may be obsolete in the case of PrEP, since ran-
dom immunization proves more efficient.
Our work has several limitations. Firstly, we consider
simplified compartmental models of both HIV and gonor-
rhea. We chose this as we were interested in performing
scenario analyses rather than quantitative predictions,
and so that we could rely on a minimal number of param-
eters. Secondly, the dataset on contacts among FSWs
and their clients is not complete, as it does not contains
non-commercial sexual acts, and might miss a certain
number of non-reported commercial ones. Finally, we do
not include neither HIV nor gonorrhea testing. Conse-
quently, we do not include the impact of treatment-as-
prevention (TasP) as a measure to reduce HIV preva-
lence. While this seems unrealistic, we preferred to focus
on prophylactic measures that directly prevent infections
among FSWs, and study their already complex interac-
tions. Notwithstanding, we believe that future scenario
analyses should include testing and treatment in order to
provide more realistic predictions.
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